Cerebral Infarction Drugs Market Size & Share, by Diagnosis (Carotid Ultrasound, Cerebral Angiogram, Echocardiogram); Drug Class {Tissue Plasminogen Activators (tPA), Anticoagulants}; Distribution Channel (Hospitals, Drug Stores, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3382
  • Published Date: Mar 15, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023-2035

Cerebral Infarction Drugs Market size is estimated to surpass USD 12053 Million by the end of 2035, witnessing around 8% CAGR during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of cerebral infarction drugs was USD 6553 Million. The growth of the market can be attributed to the increasing frequency of cerebrovascular disease, coupled with the surging prevalence of ischemic strokes throughout the world. For instance, the frequency of ischemic strokes increased to over 7.8 million new ischemic strokes by 2019, which denotes ischemic strokes accounted for more than 63% of all incident strokes worldwide. Further, the worldwide growing ratio of the geriatric population, along with an increase in hypertension rate is another significant factor anticipated to fuel the growth of the global cerebral infarction drugs market over the forecast period.

 In addition to these, factors that are believed to fuel the market growth of cerebral infarction drugs include the rise in population throughout the world as the increasing population has been affected by numerous types of disorders and cerebral infarction can affect any person of any age group. According to the World Bank report, in 2021, the total population of the world has expanded to 7.89 billion. Additionally, the growing awareness in people regarding the cerebrovascular disease, along with the surging investment in developing novel drugs is also estimated to spur market growth throughout the forecast period.


Cerebral-Infarction-Drugs-Market-scope
Get more information on this report: Request Free Sample PDF

Cerebral Infarction Drugs Sector: Growth Drivers and Challenges

Growth Drivers

  • Worldwide Growing Prevalence of Sedentary Lifestyle – Lack of physical activity can have significant health consequences. A sedentary lifestyle is gradually becoming a part of the contemporary life of people, contributing to the rapid increase of dangerous diseases such as cardiovascular disease, diabetes, obesity, cerebrovascular disease, strokes, and so on. Therefore, the growing prevalence of a sedentary lifestyle is a significant factor anticipated to boost the market growth of cerebral infarction drugs in the coming years. Based on a report, an estimated 3.6 million people die each year as a consequence of lack of physical activity, which affects about 34% of the world's population under 15 years old.

  • Rising Cases of Arterial Embolism - An arterial embolism is a clot (embolus) that has traveled from another part of the body and created an abrupt halt in blood flow to an organ or body part. Hence, the upsurge in arterial embolism is another significant factor that is estimated to proliferate the market growth in the coming years. Based on a clinical study, in non-hospitalized individuals, arterial embolism rates by 2022 varied from 0.07% (94% CI, 0.04-0.07) in the UK and Italy to 0.77% (95% CI, 0.78-0.81) in Spain. Whereas the arterial embolism rate in non-hospitalized patients in the Netherlands was around 0.9% (95% CI, 0.08-0.16), but it was 0.18% (95% CI, 0.11-0.24) in Germany. In Spain, the rate increased to around 3.09% (95% CI, 2.97-3.24) among Covid-19 patients who were hospitalized.

  • Increasing Cases of Brain Aneurysms - A brain aneurysm, also known as a cerebral aneurysm, is a thickening in a weak artery in or near the brain. Though they can develop in any part of the brain, the majority of brain aneurysms form in the large arteries running down the base of the skull. Hence, the surge in brain aneurysm and its complexities is also increasing the stances of cerebral infarction, which is further estimated to spike the market growth in the forecast period. For instance, currently, in the United States, an estimated 6.7 million people have an unruptured cerebral aneurysm.

  • Growing Ratio of Aged Population - According to the World Health Organization estimates, the world's population of adults aged 60 and more is expected to increase substantially by 2.1 million by 2050. Moreover, between 2020 and 2050, the number of persons aged 80 and more is expected to triple, hitting 426 million.

  • Rising Ratio of Clinical Trials and Their Positive Outcomes – For instance, in February 2022, Acticor Biotech SA disclosed favorable results from its ACTIMIS Phase Ib/IIa clinical trial of glenzocimab as an add-on treatment to the recommended treatment for patients with acute ischemic stroke (AIS). The results demonstrated that the trial exceeded the primary outcome, proving glenzocimab's favorable effectiveness and safety.

Challenges

  • Risk of Side Effects Associated with the Treatment – Several times, the associated side effects may occur during the treatment of ischemic stroke. Risks, such as the development of angioedema which is a life-threatening condition caused by the use of alteplase treatment. Hence, the associated risk of side effects is estimated to hinder market growth in the coming years.
  • Low Awareness Among People in Emerging Nations Regarding the Cerebral Infarction
  • Inadequacy of Preclinical Testing in Emerging Nations

Cerebral Infarction Drugs Market: Key Insights

Base Year

   2022

Forecast Year

  2023-2035

CAGR

  ~8%

 Base Year Market Size (2022)

  ~ USD 6553 Million

         Forecast Year Market Size (2035)

  ~ USD 12053 Million

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Cerebral Infarction Drugs Segmentation

Distribution Channel (Hospitals, Drug Stores, Online Pharmacies)

The cerebral infarction drugs market is segmented and analyzed for demand and supply by distribution channel into hospitals, drug stores, online pharmacies, and others. Out of these four segments, the hospitals segment is estimated to gain the largest market share of about 56% in the year 2035. The growth of the segment can be attributed to the worldwide surging patient pool in hospitals to get efficient treatment and drugs for cerebrovascular disease, and ischemic strokes. For instance, in France, around 98,450 people were hospitalized for ischemic strokes and around 19,898 for intracerebral hemorrhage in 2019. In addition to this, the radically rising prevalence of the cerebrovascular disease among people, coupled with increasing stances of ischemic strokes are also estimated to boost the segment growth throughout the forecast period.

Drug Class {Tissue Plasminogen Activators (tPA), Anticoagulants}

The  cerebral infarction drugs market is also segmented and analyzed for demand and supply by drug class into tissue plasminogen activators (tPA), anticoagulants, and others. Amongst these three segments, the tissue plasminogen activators (tPA) segment is expected to garner a significant share of around 65% in the year 2035. The growth of the segment can be credited to the effectiveness of the tissue plasminogen activators (tPA) drugs in the treatment of cerebral infarction, and ischemic strokes, followed by its efficiency to restore blood flow by dissolving the clots in a blood vessel by activating the conversion of plasminogen to plasmin, an enzyme accountable for the breakdown of clots. On the other hand, the anticoagulants segment is projected to witness a notable CAGR during the forecast period, owing to their effectiveness as anticoagulants reduce the risk of an ischemic stroke or other embolic occurrences by more than two-thirds. Moreover, the surge in novel anticoagulant development is another factor anticipated to drive the growth of the market. For instance, Warfarin and some other newer anticoagulants function equally well in the long-term therapy of venous thromboembolism to avoid blood clots. One clot is avoided for every 15 persons who take any anticoagulant. 

Our in-depth analysis of the global market includes the following segments:

      By Diagnosis

  • Carotid Ultrasound
  • Cerebral Angiogram
  • Echocardiogram
  • Others

      By Drug Class

  • Tissue Plasminogen Activators (tPA)
  • Anticoagulants
  • Others

     By Distribution Channel

  • Hospitals
  • Drug Stores
  • Online Pharmacies
  • Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Cerebral Infarction Drugs Industry - Regional Synopsis

North American Market Forecast   

The North American cerebral infarction drugs market, amongst the market in all the other regions, is projected to hold the largest market share of about 50% by the end of 2035. The growth of the market can be attributed majorly to the increasing frequency of cerebrovascular disease amongst several people, backed by the sedentary lifestyle of individuals. For instance, the fifth most common cause of mortality in the United States and the most frequent type of brain injury that poses a serious risk to life is a cerebrovascular disease which contributed to more than 168,000 deaths in 2020. In addition, the region's escalating healthcare industry, and rising proportion of obesity, and hypertension rates in the population of the United States and Canada are also anticipated to boost the market growth during the forecast period. In addition to this, the increasing approval for novel drug delivery systems and treatments is another significant factor that is projected to further boost the market growth in the region during the projected time frame.

APAC Market Statistics

The Asia Pacific cerebral infarction drugs market, amongst the market in all the other regions, is projected to hold the second largest share of about 20% during the forecast period. The growth of the market can be attributed majorly to the rising geriatric population, and the advancing healthcare system. Based on the statistics of the World Bank, the population above 65 years of age in India crossed 90,719,952 in 2020, while, it crossed 167,808,567 in China. Moreover, rising healthcare expenditure and surging investment in R&D activities is also estimated to boost the market growth further throughout the projected time frame in the APAC region.

Europe Market Forecast

Further, the market in the European region, amongst the market in all the other regions, is projected to hold a majority of the share of about 15% by the end of 2035. The growth of the market can be attributed majorly to the increasing frequency of hypertension, coupled with the escalating prevalence of atherosclerosis among people in the region. Further, the existence of a strong healthcare network in the region, along with the region's expanding healthcare industry, and rise in novel drug developments are also anticipated to boost the market growth during the forecast period. 

Research Nester
Cerebral-Infarction-Drugs-Market-Regional
Get more information on this report: Request Free Sample PDF

Companies Dominating the Cerebral Infarction Drugs Landscape

top-features-companies
    • Amgen Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Sanofi-aventis Groupe
    • Abbott Laboratories
    • Merck & Co., Inc.
    • Boehringer Ingelheim International GmbH
    • Amneal Pharmaceuticals, Inc.
    • Novartis AG
    • Pfizer Inc.
    • Edwards Lifesciences Corporation
    • Daiichi Sankyo Company, Limited

In the News

  • Abbott Laboratories declared that the FDA has given the approval to its Amplatzer Amulet Left Atrial Appendage Occluder device to treat persons with atrial fibrillation (AFib) who are at a higher risk for an ischemic stroke. The device provides prompt closure of the left atrial appendage (LAA), which lowers stroke risk and prevents the immediate requirement for blood-thinning medicines in persons with AFib.

  • Daiichi Sankyo Company, Limited declared the accomplishment of the primary endpoint in the Japan PRASTRO-III phase 3 study of the antiplatelet agent, prasugrel hydrochloride in thrombotic stroke patients. The clinical study was conducted in a double-blind comparative method to evaluate the effectiveness and safety of prasugrel and clopidogrel in 234 thrombotic stroke patients with one or more risk factors for ischemic stroke recurrence.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3382
  • Published Date: Mar 15, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Worldwide growing prevalence of sedentary lifestyle, rising cases of arterial embolism, and rising ratio of clinical trials and their positive outcomes are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2023-2035.

Risk of side effects associated with the treatment, and low awareness among people in emerging nations regarding the cerebral infarction are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Amgen Inc., Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Amneal Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by diagnosis, drug class, distribution channel, and by region.

The hospitals segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Cerebral Infarction Drugs Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying